The experience of community pharmacy in SARS-CoV-2 antigen detection tests programs
e202302010
Keywords:
COVID-19, SARS-CoV-2, Farmacia comunitaria, Antigen detection test, Self-diagnosis test, Community pharmacy, PharmacistsAbstract
SARS-CoV-2 infection was an unprecedented pandemic with unprecedented global health and socio-economic impact. More than 13 million cases had been confirmed in Spain by August 2022, and diagnostic testing to detect cases of infection in the country has helped to partially mitigate the spread of the virus. In 2021, the first self-testing antigen tests were marketed for dispensing in community pharmacies, and over-the-counter dispensing was allowed from July of that year. The network of community pharmacies played a key role, not only in the informed dispensing of these tests, but also in actively participating in the performance, supervision and reporting of results to the health authorities, and even in the issuing of digital certificates.
A compilation has been made of all the available data on the subject, with a deadline of 13 February 2022, which is considered to be the end of the sixth wave of the epidemic in Spain. The results of the action taken by community pharmacies in twelve Autonomous Communities, which somehow participated in these initiatives by carrying out or supervising a total of 1,043,800 tests, from which 109,570 positive cases (10.5% of the total) were detected and reported to the National Health System, are presented in this article. Although the results are provisional, because many of the programmes are still ongoing, they are a clear demonstration of the potential that community pharmacies can play in Public Health work.
Downloads
References
Medeiros de Figueiredo A, Daponte A, Moreira Marculino de Figueiredo DC, Gil-García E, Kalache A. Letalidad de la COVID-19: ausencia de patrón epidemiológico. Gac Sanit. 2021; 35(4): 355-357.
León-Gómez I, Mazagatos C, Delgado-Sanz C, Frías L, Vega-Piris L, Rojas-Benedicto A, Larrauri A. The Impact of COVID-19 on Mortality in Spain: Monitoring Excess Mortality (MoMo) and the Surveillance of Confirmed COVID-19 Deaths. Viruses. 2021; 13(12): 2423.
Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022; S1473-3099(22)00320-6.
Li Y, Liang M, Gao L, Ayaz Ahmed M, Uy JP, Cheng C, Zhou Q, Sun C. Face masks to prevent transmission of COVID-19: A systematic review and meta-analysis. Am J Infect Control. 2021; 49(7): 900-906.
Jiang JC, Zhang Y. Serological antibody testing in the COVID-19 pandemic: their molecular basis and applications. Biochem Soc Trans. 2020; 48(6): 2851-2863.
Chaimayo C, Kaewnaphan B, Tanlieng N, Athipanyasilp N, Sirijatuphat R, Chayakulkeeree M et al. Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand. Virol J. 2020; 17(1): 177.
Kumar CK, Balasubramanian R, Ongarello S, Carmona S, Laxminarayan R. SARS-CoV-2 testing strategies for outbreak mitigation in vaccinated populations. PLoS One. 2022; 17(7): e0271103.
Soriano JB, Gerli AG, Centanni S, Ancochea J. Forecasting COVID-19 Infection Trends and New Hospital Admissions in Spain due to SARS-CoV-2 Variant of Concern Omicron. Arch Bronconeumol. 2022; 58(2): 200-202.
Del Águila-Mejía J, Wallmann R, Calvo-Montes J, Rodríguez-Lozano J, Valle-Madrazo T, Aginagalde-Llorente A. Secondary Attack Rate, Transmission and Incubation Periods, and Serial Interval of SARS-CoV-2 Omicron Variant, Spain. Emerg Infect Dis. 2022; 28(6): 1224-1228.
De Michelena P, Torres I, Ramos-García Á, Gozalbes V, Ruiz N, Sanmartín A et al. Real-life performance of a COVID-19 rapid antigen detection test targeting the SARS-CoV-2 nucleoprotein for diagnosis of COVID-19 due to the Omicron variant. J Infect. 2022; 84(5): e64-e66.
Boletín Oficial del Estado. Real Decreto Legislativo 1/2015, de 24 de julio, por el que se aprueba el texto refundido de la Ley de garantías y uso racional de los medicamentos y productos sanitarios. BOE núm. 177, de 25 de julio de 2015.
Instituto de Salud Carlos III. Red Nacional de Vigilancia Epidemiológica. Informe nº 118. Situación de COVID-19 en España - 16 de febrero de 2022. Disponible en: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/-COVID-19.-Informes-previos.aspx
Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Información general sobre test de diagnóstico de COVID-19. Disponible en: https://www.aemps.gob.es/la-aemps/ultima-informacion-de-la-aemps-acerca-del-covid%e2%80%9119/informacion-general-sobre-tests-de-diagnostico-de-covid-19/
García R, Tardio J, Perales E, De Toro A, De los Santos L, Adiego J. Seguimiento para la realización, trazabilidad y seguimiento de los resultados de test de antígenos de SARS-COV-2. Farm Com. 2022; 14(Supl 1. Congreso SEFAC): 174.
Mak GC, Cheng PK, Lau SS, Wong KK, Lau CS, Lam ET, Chan RC, Tsang DN. Evaluation of rapid antigen test for detection of SARS-CoV-2 virus. J Clin Virol. 2020; 129:104500.
Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes MÁ et al. Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres. Clin Microbiol Infect. 2021; 27(3): 472.e7-472.e10.
Amariles P, Ledezma-Morales M, Salazar-Ospina A, Hincapié-García JA. How to link patients with suspicious COVID-19 to health system from the community pharmacies? A route proposal. Res Social Adm Pharm. 2021; 17(1): 1988-1989.
Wulandari LPL, Sawitri AAS, Hermansyah A. The potential roles of pharmacy medication sales data to augment the syndromic surveillance system in response to COVID-19 and preparedness for other future infectious disease outbreaks in Indonesia. Int J Health Plann Manage. 2022; 37(1): 30-39.
De Ridder D, Loizeau AJ, Sandoval JL, Ehrler F, Perrier M, Ritch A et al. Detection of Spatiotemporal Clusters of COVID-19-Associated Symptoms and Prevention Using a Participatory Surveillance App: Protocol for the @choum Study. JMIR Res Protoc. 2021; 10(10): e30444.
Merencio E, Jané I, Busquets A, Mestres C, Burniol M, Tous S et al. Papel del farmacéutico comunitario en la quinta y sexta ola de la pandemia de SARS-Cov2 en Cataluña. Farm. comunitarios (Internet). 2022; 14(Supl 1): 1. Disponible en: https://www.farmaceuticoscomunitarios.org/sites/default/files/import/14/pdf/239.pdf
Deleito O. Nuevo servicio SARS-COV-2 implantado en farmacia comunitaria. Evidencia de la ayuda que pueden prestar las farmacias comunitarias en la pandemia. Farm. comunitarios (Internet). 2022; 14(Supl 1): 1. https://www.farmaceuticoscomunitarios.org/sites/default/files/import/14/pdf/57.pdf
Zozaya N, Fernández I, Blanes A, Varas R, Peiró T. Vacunación frente a la COVID-19 en España: encuestas en la farmacia comunitaria. Ed. Fundación Weber. 2021. ISBN: 978-84-122101-9-4. Disponible en: farmaceuticos.com/wp-content/uploads/2022/01/Informe-Vacunacion-frente-COVID-19-en-Espana.pdf
Published
Versions
- 2023-02-07 (2)
- 2023-02-07 (1)
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Carlos Fernández Moriano, Tamara Peiró Zorrilla, Iván A. Espada Ibáñez, Paula Mateos Sánchez, Tamara Dorado Romero, Antonio Blanes Jiménez
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
